Research programme: recombinant human insulin - Adocia

Drug Profile

Research programme: recombinant human insulin - Adocia

Alternative Names: BioChaperone Lispro U300; Combo insulin fast and slow - Adocia; insulin glulisine/insulin aspart - Adocia; Ultra-concentrated prandial insulin - Adocia

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Adocia
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 27 Jan 2017 Research programme: recombinant human insulin - Adocia is available for licensing as of 27 Jan 2017. http://www.adocia.fr/WP/
  • 27 Jan 2017 Eli Lilly terminated the agreement which was signed in December 2014 with Adocia for the joint development and commercialisation of BioChaperone® Lispro
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in France (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top